Lessons and insights from ABO-incompatible lung transplantation

G. I. Snell, M. Holmes, B. J. Levvey, A. Shipp, C. Robertson, G. P. Westall, S. Cohney

Research output: Contribution to journalArticleOtherpeer-review

7 Citations (Scopus)

Abstract

With ABO blood group incompatibility (ABOi) between donor and recipient becoming a part of mainstream living-donor renal transplantation, the applicability of ABOi to other areas of transplantation is being reconsidered. Here we present a case of inadvertent ABOi lung retransplantation managed successfully with initial plasmapheresis, antithymocyte globulin and intravenous immunoglobulin; and subsequently with oral cyclophosphamide and sirolimus in addition to tacrolimus and prednisolone. Interestingly, in the setting of solid levels of tacrolimus and sirolimus, the patient developed a fatal thrombotic microangiopathy of uncertain origin subsequent to the cessation of cyclophosphamide at 9 years posttransplant. It is apparent that ABOi lung transplantation can result in surprisingly successful long-term outcomes. Low pretransplant antibody titers likely aid this and, in pediatric neonatal or infant cases, this may not be uncommon. We must proceed cautiously as there are significant risks. Understanding the monitoring, prevention and treatment of lung transplant antibody-mediated rejection, while avoiding the long-term complications of overimmunosuppression, will be the keys to the success of future cases. A case of an inadvertent ABO-incompatible lung transplant suggests some low-titer ABO antibody recipients can achieve long-term survival.

Original languageEnglish
Pages (from-to)1350-1353
Number of pages4
JournalAmerican Journal of Transplantation
Volume13
Issue number5
DOIs
Publication statusPublished - May 2013

Keywords

  • ABO-incompatibility
  • hemolytic uremic syndrome
  • lung transplantation
  • thrombotic microangiopathy

Cite this